(BDX) Becton Dickinson - Ratings and Ratios
Syringes, Catheters, Diagnostics, Infusion, Analyzers
Dividends
| Dividend Yield | 2.10% |
| Yield on Cost 5y | 1.93% |
| Yield CAGR 5y | 5.00% |
| Payout Consistency | 77.7% |
| Payout Ratio | 28.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 25.4% |
| Value at Risk 5%th | 38.8% |
| Relative Tail Risk | -7.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.29 |
| Alpha | -16.89 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.323 |
| Beta | 0.510 |
| Beta Downside | 0.673 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.06% |
| Mean DD | 16.28% |
| Median DD | 15.57% |
Description: BDX Becton Dickinson December 03, 2025
Becton Dickinson (NYSE:BDX) is a diversified medical-technology firm that designs, manufactures and sells a broad portfolio of products across three main segments: BD Medical (IV and infusion devices, medication safety and pharmacy automation), BD Life Sciences (specimen collection, microbiology and molecular diagnostics, flow cytometry and single-cell analysis reagents) and BD Interventional (hernias, soft-tissue repair, biosurgery and critical-care devices). Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves hospitals, clinics, research labs and pharmaceutical companies worldwide.
Key recent metrics (FY 2023) show total revenue of roughly $20.2 billion, with the Life Sciences segment contributing about $7 billion and delivering a 14 % operating margin-higher than the Medical segment’s 12 % margin, reflecting strong demand for diagnostic automation and single-cell genomics. The segment’s growth is driven by macro-level factors such as the aging U.S. population, rising outpatient procedural volumes, and a 5 % CAGR expansion in global in-vitro diagnostics spending. Additionally, BD’s ongoing investment in digital pharmacy solutions aligns with the broader health-care trend toward automation and inventory optimization, which analysts estimate could improve supply-chain efficiency by up to 8 %.
For a deeper, data-driven assessment of BDX’s valuation and scenario analysis, the ValueRay platform offers granular financial models and up-to-date market insights.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.60b TTM) > 0 and > 6% of Revenue (6% = 1.33b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -0.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.24% (prev 7.49%; Δ -3.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 5.64b > Net Income 1.60b (YES >=105%, WARN >=100%) |
| Net Debt (18.54b) to EBITDA (3.48b) ratio: 5.32 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (285.4m) change vs 12m ago -1.79% (target <= -2.0% for YES) |
| Gross Margin 45.40% (prev 45.36%; Δ 0.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.47% (prev 35.22%; Δ 4.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.66 (EBITDA TTM 3.48b / Interest Expense TTM 616.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.88
| (A) 0.02 = (Total Current Assets 9.26b - Total Current Liabilities 8.31b) / Total Assets 55.33b |
| (B) 0.30 = Retained Earnings (Balance) 16.62b / Total Assets 55.33b |
| (C) 0.03 = EBIT TTM 1.64b / Avg Total Assets 56.31b |
| (D) 0.57 = Book Value of Equity 16.99b / Total Liabilities 29.93b |
| Total Rating: 1.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.74
| 1. Piotroski 4.50pt |
| 2. FCF Yield 3.61% |
| 3. FCF Margin 11.83% |
| 4. Debt/Equity 0.76 |
| 5. Debt/Ebitda 5.32 |
| 6. ROIC - WACC (= -2.47)% |
| 7. RoE 6.31% |
| 8. Rev. Trend 86.55% |
| 9. EPS Trend 56.46% |
What is the price of BDX shares?
Over the past week, the price has changed by +3.05%, over one month by +9.82%, over three months by +5.86% and over the past year by -8.47%.
Is BDX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 202.6 | 2.1% |
| Analysts Target Price | 202.6 | 2.1% |
| ValueRay Target Price | 208 | 4.8% |
BDX Fundamental Data Overview December 10, 2025
P/E Trailing = 32.5601
P/E Forward = 12.6582
P/S = 2.487
P/B = 2.1302
P/EG = 0.9737
Beta = 0.277
Revenue TTM = 22.22b USD
EBIT TTM = 1.64b USD
EBITDA TTM = 3.48b USD
Long Term Debt = 17.62b USD (from longTermDebt, last quarter)
Short Term Debt = 855.0m USD (from shortTermDebt, last quarter)
Debt = 19.18b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 18.54b USD (from netDebt column, last quarter)
Enterprise Value = 72.86b USD (54.32b + Debt 19.18b - CCE 641.0m)
Interest Coverage Ratio = 2.66 (Ebit TTM 1.64b / Interest Expense TTM 616.0m)
FCF Yield = 3.61% (FCF TTM 2.63b / Enterprise Value 72.86b)
FCF Margin = 11.83% (FCF TTM 2.63b / Revenue TTM 22.22b)
Net Margin = 7.19% (Net Income TTM 1.60b / Revenue TTM 22.22b)
Gross Margin = 45.40% ((Revenue TTM 22.22b - Cost of Revenue TTM 12.13b) / Revenue TTM)
Gross Margin QoQ = 47.51% (prev 47.50%)
Tobins Q-Ratio = 1.32 (Enterprise Value 72.86b / Total Assets 55.33b)
Interest Expense / Debt = 0.81% (Interest Expense 155.0m / Debt 19.18b)
Taxrate = 3.33% (17.0m / 510.0m)
NOPAT = 1.59b (EBIT 1.64b * (1 - 3.33%))
Current Ratio = 1.11 (Total Current Assets 9.26b / Total Current Liabilities 8.31b)
Debt / Equity = 0.76 (Debt 19.18b / totalStockholderEquity, last quarter 25.39b)
Debt / EBITDA = 5.32 (Net Debt 18.54b / EBITDA 3.48b)
Debt / FCF = 7.05 (Net Debt 18.54b / FCF TTM 2.63b)
Total Stockholder Equity = 25.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 1.60b / Total Assets 55.33b)
RoE = 6.31% (Net Income TTM 1.60b / Total Stockholder Equity 25.31b)
RoCE = 3.82% (EBIT 1.64b / Capital Employed (Equity 25.31b + L.T.Debt 17.62b))
RoIC = 3.57% (NOPAT 1.59b / Invested Capital 44.46b)
WACC = 6.03% (E(54.32b)/V(73.50b) * Re(7.89%) + D(19.18b)/V(73.50b) * Rd(0.81%) * (1-Tc(0.03)))
Discount Rate = 7.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.03%
[DCF Debug] Terminal Value 79.85% ; FCFE base≈2.81b ; Y1≈3.14b ; Y5≈4.18b
Fair Price DCF = 253.8 (DCF Value 72.44b / Shares Outstanding 285.4m; 5y FCF grow 13.83% → 3.0% )
EPS Correlation: 56.46 | EPS CAGR: 2.27% | SUE: 0.27 | # QB: 0
Revenue Correlation: 86.55 | Revenue CAGR: 6.10% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.37 | Chg30d=-0.152 | Revisions Net=-6 | Analysts=9
EPS current Year (2026-09-30): EPS=14.94 | Chg30d=+0.050 | Revisions Net=-2 | Growth EPS=+3.7% | Growth Revenue=+3.2%
EPS next Year (2027-09-30): EPS=15.91 | Chg30d=-0.134 | Revisions Net=-2 | Growth EPS=+6.5% | Growth Revenue=+3.6%
Additional Sources for BDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle